US 2021/0260052 A1Published application

Selective estrogen receptor degraders

AssigneeEli Lilly and Company

InventorsJeffrey Daniel COHEN, Daniel Jon SALL

Life of this patent

Estimating the term…

Abstract

Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts, pharmaceutical compositions, uses, and methods of use thereof are provided.

Claims12

Dependent claims

A compound of the formula

or a pharmaceutically acceptable salt thereof.

Dependencies are inferred from the claim text.

Facts

Application: 17/254,991Filed 11 Jul 2019
Priority: 12 Jul 2018
Published: 26 Aug 2021
Term ends: Not estimatedThe source records don’t support an estimate.

Classification8 codes

A61K 31/4709
Quinolines; Isoquinolines: non-condensed quinolines and containing further heterocyclic rings
C07D 491/052
With only one oxygen atom as ring hetero atom in the oxygen-containing ring: the oxygen-containing ring being six-membered
A61K 9/0053
Galenical forms characterised by the site of application: mouth and digestive tract, i.e. intraoral and peroral administration
A61P 35/00
Antineoplastic agents

Family

Application62/697,100Us provisional application · filed 12 Jul 2018
Application62/825,172Us provisional application · filed 28 Mar 2019
US 12,128,040 B2Related patent
US 2021/0260052 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

patentgrepSearch patents

Back to results